Anergis discovers and develops proprietary, pharmaceutical-grade COP allergy vaccines for ultra-fast Allergy Immunotherapy based on its unique technology of Contiguous Overlapping Peptides (COP).

  • COPs are long synthetic peptides (up to 80 amino acids), reproducing fragments of the amino acid sequence of a selected major allergen(s), such as sequences of the protein Bet v 1, the major allergen in birch pollen.
  • A COP allergy vaccine is a set of selected COPs derived from the same allergen, which reproduce - but in separate molecules - the entire sequence of the naturally occurring allergen and present sequence overlaps at their terminal ends.
  • COP allergy vaccines contain all linear epitopes of the original allergen to achieve optimal immunogenicity, without the three-dimensional structure of the allergen protein, which is known to be essential in eliciting the allergic reaction (through conformational IgE epitopes).



The COP technology allows to design new vaccines for the most common allergies (inhaled, insect stings, food). As of today, Anergis has designed peptides and conducted preclinical and/or clinical research on COP allergy vaccines for :

  • bee venom
  • birch pollen
  • ragweed pollen
  • dust mites


  • Biopôle Building SC-A
    Route de la Corniche 4
    CH-1066 Epalinges
  • Email:

This website uses cookies to ensure you get the best experience on our website.